• Head and Neck Disease Site Group. Winquist E, Oliver T, Gilbert R. The role of postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck. Toronto (ON): Cancer Care Ontario (CCO); 2004 Dec. 20 p. (Evidence-based series; no. 5-10). [13 references]

• Postoperative adjuvant chemoradiotherapy is recommended as an effective treatment approach to improve control and survival outcomes for those patients at a high risk of recurrence who are willing and deemed able to tolerate the addition of chemotherapy to radiotherapy.
• The recommended postoperative adjuvant chemoradiotherapy regimen is 100mg/m² of cisplatin administered every 21 days for three cycles concurrently with standard doses of conventionally fractionated radiotherapy.

None provided

The recommendations are supported by randomized controlled trials.

• Head and Neck Disease Site Group. Winquist E, Oliver T, Gilbert R. The role of postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck. Toronto (ON): Cancer Care Ontario (CCO); 2004 Dec. 20 p. (Evidence-based series; no. 5-10). [13 references]

Not applicable: The guideline was not adapted from another source.

2004 Dec

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

The Program in Evidence-based Care (PEBC), is a project supported by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

Provincial Head and Neck Cancer Disease Site Group

Members of the disease site group disclosed potential conflict of interest information. The author(s) declare that they have no competing interests.

None available

This NGC summary was completed by ECRI on August 12, 2005. The information was verified by the guideline developer on September 13, 2005.